CL2021003190A1 - Inhibidores de tead y usos de los mismos - Google Patents
Inhibidores de tead y usos de los mismosInfo
- Publication number
- CL2021003190A1 CL2021003190A1 CL2021003190A CL2021003190A CL2021003190A1 CL 2021003190 A1 CL2021003190 A1 CL 2021003190A1 CL 2021003190 A CL2021003190 A CL 2021003190A CL 2021003190 A CL2021003190 A CL 2021003190A CL 2021003190 A1 CL2021003190 A1 CL 2021003190A1
- Authority
- CL
- Chile
- Prior art keywords
- tead
- inhibitors
- tead inhibitors
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Abstract
La presente invención proporciona compuestos, sus composiciones y sus métodos de uso.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962855082P | 2019-05-31 | 2019-05-31 | |
US201962928931P | 2019-10-31 | 2019-10-31 | |
US201962944567P | 2019-12-06 | 2019-12-06 | |
US202063025219P | 2020-05-15 | 2020-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021003190A1 true CL2021003190A1 (es) | 2022-09-30 |
Family
ID=71833411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021003190A CL2021003190A1 (es) | 2019-05-31 | 2021-11-30 | Inhibidores de tead y usos de los mismos |
Country Status (15)
Country | Link |
---|---|
US (3) | US11274082B2 (es) |
EP (1) | EP3976194A2 (es) |
JP (1) | JP2022534426A (es) |
KR (1) | KR20220030222A (es) |
CN (1) | CN114466839A (es) |
AU (1) | AU2020282757A1 (es) |
BR (1) | BR112021024108A2 (es) |
CA (1) | CA3142351A1 (es) |
CL (1) | CL2021003190A1 (es) |
CO (1) | CO2021016015A2 (es) |
IL (1) | IL288384A (es) |
MX (1) | MX2021014443A (es) |
SG (1) | SG11202113129UA (es) |
TW (1) | TW202108571A (es) |
WO (1) | WO2020243415A2 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11827634B2 (en) | 2019-05-31 | 2023-11-28 | Janssen Pharmaceutica Nv | Small molecule inhibitors of NF-kB inducing kinase |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022534425A (ja) | 2019-05-31 | 2022-07-29 | イケナ オンコロジー, インコーポレイテッド | Tead阻害剤およびその使用 |
TW202108571A (zh) | 2019-05-31 | 2021-03-01 | 美商醫肯納腫瘤學公司 | Tead抑制劑及其用途 |
WO2022120355A1 (en) * | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
WO2022120353A1 (en) * | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
KR20230149885A (ko) | 2021-01-25 | 2023-10-27 | 이케나 온콜로지, 인코포레이티드 | 폐암 치료에 사용하기 위한 3-(이미다졸-4-일)-4-(아미노)-벤젠설폰아마이드 tead 저해제와 egfr 저해제 및/또는 mek 저해제의 조합 |
WO2022177869A1 (en) * | 2021-02-18 | 2022-08-25 | Merck Sharp & Dohme Llc | Aryl ether compounds as tead modulators |
CN113072479A (zh) * | 2021-03-26 | 2021-07-06 | 罗田县新普生药业有限公司 | 一种从褪黑素结晶母液中提取褪黑素的方法 |
AU2022258968A1 (en) | 2021-04-16 | 2023-10-19 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
CN115466243A (zh) * | 2021-06-11 | 2022-12-13 | 武汉人福创新药物研发中心有限公司 | 用于tead抑制剂的杂环化合物 |
CN115594680A (zh) * | 2021-07-07 | 2023-01-13 | 武汉人福创新药物研发中心有限公司(Cn) | 一种tead抑制剂 |
CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
AU2022340987A1 (en) | 2021-09-01 | 2024-01-18 | Novartis Ag | Dosing regimen for a tead inhibitor |
WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2023143354A1 (zh) * | 2022-01-30 | 2023-08-03 | 希格生科(深圳)有限公司 | 三环化合物及其应用 |
WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023183763A1 (en) * | 2022-03-21 | 2023-09-28 | Chemocentryx, Inc. | Cxcr6 sulfonamide compounds |
WO2023204822A1 (en) * | 2022-04-22 | 2023-10-26 | Vivace Therapeutics, Inc. | Phenyl phosphine oxide compounds and methods of use thereof |
WO2023211889A1 (en) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Polymorphic compounds and uses thereof |
US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
CN117756855A (zh) * | 2022-09-23 | 2024-03-26 | 杭州天玑济世生物科技有限公司 | 具有磷酰化芳基结构的小分子化合物及其应用 |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3120564A (en) | 1960-01-13 | 1964-02-04 | American Cyanamid Co | Alkenoylamino benzophenones |
ZA825719B (en) | 1981-09-03 | 1983-06-29 | Recordati Chem Pharm | Alkanoylanilides |
JPS58179838A (ja) | 1982-04-14 | 1983-10-21 | Konishiroku Photo Ind Co Ltd | 画像形成方法 |
US5256791A (en) | 1992-03-02 | 1993-10-26 | Pfizer Inc. | Preparation of intermediates in the synthesis of quinoline antibiotics |
DE4341403A1 (de) | 1993-12-04 | 1995-06-08 | Basf Ag | N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung |
US5475116A (en) | 1994-04-29 | 1995-12-12 | Pfizer Inc. | Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones |
JPH0912547A (ja) | 1995-06-23 | 1997-01-14 | Chisso Corp | ニューキノロン系化合物中間体の製造方法 |
AU1671597A (en) | 1996-02-13 | 1997-09-02 | Chugai Seiyaku Kabushiki Kaisha | Indole derivatives |
JPH1072434A (ja) * | 1996-04-08 | 1998-03-17 | Nissan Chem Ind Ltd | 2,4−置換アニリン誘導体 |
US5968929A (en) | 1996-10-30 | 1999-10-19 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
US7019142B2 (en) | 1998-01-16 | 2006-03-28 | Pfizer Inc. | Process for preparing naphthyridones and intermediates |
US6184380B1 (en) | 1999-01-25 | 2001-02-06 | Pfizer Inc. | Process for preparing naphthyridones and intermediates |
US6590118B1 (en) | 1999-09-29 | 2003-07-08 | Novo Nordisk A/S | Aromatic compounds |
AP2002002596A0 (en) | 2000-02-11 | 2002-09-30 | Vertex Pharma | Piperazine and piperidine derivatives. |
ATE324365T1 (de) * | 2000-08-31 | 2006-05-15 | Pfizer | Phenoxyphenylheterozyklen als serotonin- wiederaufnahmehemmer |
JP2004511558A (ja) | 2000-10-19 | 2004-04-15 | ファイザー・プロダクツ・インク | 架橋ピペラジン誘導体 |
DE60202452C5 (de) | 2001-03-30 | 2006-11-23 | Pfizer Products Inc., Groton | Pyridazinonaldose reductase inhibitoren |
EP1417204B1 (en) * | 2001-08-15 | 2006-01-18 | E. I. du Pont de Nemours and Company | Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests |
US20040034019A1 (en) | 2002-08-08 | 2004-02-19 | Ronald Tomlinson | Piperazine and piperidine derivatives |
US20040082641A1 (en) | 2002-10-28 | 2004-04-29 | Rytved Klaus Asger | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases |
EP1558245A2 (en) | 2002-10-28 | 2005-08-03 | Novo Nordisk A/S | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases |
DE60227576D1 (de) | 2002-12-10 | 2008-08-21 | Ranbaxy Lab Ltd | 3,6-DISUBSTITUIERTE AZABICYCLO i3.1.0 -HEXANDERIVATIVE ALS ANTAGONISTEN DES MUSCARINREZEPTORS |
ATE386738T1 (de) | 2002-12-23 | 2008-03-15 | Ranbaxy Lab Ltd | Flavaxat-derivate als muscarin-rezeptor antagonisten |
AU2002356369A1 (en) | 2002-12-23 | 2004-07-14 | Ranbaxy Laboratories Limited | Xanthine derivatives as muscarinic receptor antagonists |
US7488748B2 (en) | 2003-01-28 | 2009-02-10 | Ranbaxy Laboratories Limited | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
UA86037C2 (ru) | 2003-10-14 | 2009-03-25 | Пфайзер Продактс Инк. | Бициклические [3.1.0] производные, как ингибиторы переносчика глицина |
EP1717225A4 (en) | 2004-02-18 | 2009-10-21 | Kyorin Seiyaku Kk | BICYCLIC AMIDE DERIVATIVES |
ATE444066T1 (de) | 2004-06-22 | 2009-10-15 | Schering Corp | Liganden für den cannabinoidrezeptoren |
DE102004039280A1 (de) * | 2004-08-13 | 2006-02-23 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole |
MX2007002136A (es) | 2004-09-01 | 2007-04-02 | Pfizer Prod Inc | Antagonistas amino azabiciclicos del receptor 3 de la histamina. |
EP1828174A1 (en) | 2004-11-19 | 2007-09-05 | Ranbaxy Laboratories Limited | Azabicyclic muscarinic receptor antagonists |
CN1944398A (zh) | 2005-01-11 | 2007-04-11 | 中国医学科学院药物研究所 | 新的苯甲酰胺类化合物及其制法和药物用途 |
AP2007004198A0 (en) | 2005-04-08 | 2007-10-31 | Pfizer Prod Inc | Bicyclic [3.1.0] heteroaryl amides as type I glycine transport inhibitors |
US20090124600A1 (en) | 2005-04-19 | 2009-05-14 | Layton Mark E | N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists |
AU2006244206A1 (en) | 2005-05-10 | 2006-11-16 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of ion channels |
GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
WO2007029086A2 (en) | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors |
EP1948164A1 (en) | 2005-10-19 | 2008-07-30 | Ranbaxy Laboratories, Ltd. | Pharmaceutical compositions of muscarinic receptor antagonists |
US7560551B2 (en) | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
WO2008010061A2 (en) | 2006-07-17 | 2008-01-24 | Glenmark Pharmaceuticals S.A. | 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation |
GB2454615A (en) | 2006-07-21 | 2009-05-13 | Lupin Ltd | Antidiabetic azabicyclo (3.1.0) hexan compounds |
WO2008029349A2 (en) | 2006-09-04 | 2008-03-13 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
EP2129660A2 (en) | 2006-12-19 | 2009-12-09 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
EP2132196A1 (en) | 2007-02-26 | 2009-12-16 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
WO2008117229A1 (en) | 2007-03-23 | 2008-10-02 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
PE20091017A1 (es) | 2007-10-31 | 2009-07-16 | Janssen Pharmaceutica Nv | Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa |
WO2009152027A1 (en) | 2008-06-12 | 2009-12-17 | Merck & Co., Inc. | 5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition |
MX2011004470A (es) | 2008-10-29 | 2011-05-31 | Celgene Corp | Compuestos de isoindolina para uso en el tratamiento de cancer. |
US9149465B2 (en) | 2009-05-18 | 2015-10-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
AR076687A1 (es) | 2009-05-18 | 2011-06-29 | Infinity Pharmaceuticals Inc | Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen |
CN103140134B (zh) | 2010-07-23 | 2015-07-29 | 默沙东公司 | 新吡咯烷衍生的β3肾上腺素能受体激动剂 |
TW201311679A (zh) | 2011-08-04 | 2013-03-16 | Takeda Pharmaceutical | 含氮雜環化合物 |
EP2755656B1 (en) | 2011-09-16 | 2016-09-07 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
TWI566701B (zh) | 2012-02-01 | 2017-01-21 | 日本農藥股份有限公司 | 芳烷氧基嘧啶衍生物及包含該衍生物作為有效成分的農園藝用殺蟲劑及其使用方法 |
EP2925322B1 (en) | 2012-11-29 | 2018-10-24 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9505781B2 (en) | 2013-03-13 | 2016-11-29 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
AU2014229283B2 (en) | 2013-03-14 | 2016-07-28 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH |
KR101556318B1 (ko) | 2013-05-15 | 2015-10-01 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체 |
WO2014199164A1 (en) | 2013-06-12 | 2014-12-18 | Ampla Pharmaceuticals, Inc. | Diaryl substituted heteroaromatic compounds |
AR105889A1 (es) | 2015-09-03 | 2017-11-22 | Actelion Pharmaceuticals Ltd | Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos |
EP3353156B1 (en) | 2015-09-23 | 2021-11-03 | The General Hospital Corporation | Tead transcription factor autopalmitoylation inhibitors |
US20170158702A1 (en) | 2015-12-02 | 2017-06-08 | Kyras Therapeutics, Inc. | Multivalent ras binding compounds |
AU2016379292B2 (en) | 2015-12-24 | 2021-03-25 | Kyowa Kirin Co., Ltd. | α, β unsaturated amide compound |
JP6990663B2 (ja) | 2016-05-31 | 2022-01-13 | シエッシ ファーマスーティシ エス.ピー.エー. | ヒト好中球エラスターゼ阻害剤としてのイミダゾロン化合物 |
US20190159450A1 (en) | 2016-06-27 | 2019-05-30 | Moghu Research Center Ltd. | Pyridine-based compound including isoxazoline ring and use thereof as herbicide |
AU2017316639B2 (en) | 2016-08-23 | 2022-09-08 | Recurium Ip Holdings, Llc | Methods for cross coupling |
KR102173463B1 (ko) | 2016-10-11 | 2020-11-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 안드로겐 수용체의 표적 분해용 화합물 및 방법 |
CA3044259A1 (en) | 2016-12-02 | 2018-06-07 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
US11186554B2 (en) * | 2017-05-03 | 2021-11-30 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
US20200095236A1 (en) | 2017-05-10 | 2020-03-26 | Forge Therapeutics, Inc. | Antibacterial compounds |
AU2018289759B2 (en) | 2017-06-23 | 2022-03-10 | Kyowa Kirin Co., Ltd. | Alpha, beta-unsaturated amide compound |
US11192865B2 (en) * | 2017-08-21 | 2021-12-07 | Vivace Therapeutics, Inc. | Benzosulfonyl compounds |
TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
TW201920108A (zh) | 2017-09-25 | 2019-06-01 | 日商武田藥品工業有限公司 | N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物 |
US10287222B1 (en) | 2017-10-20 | 2019-05-14 | Uop Llc | Process and apparatus for desorbent recovery |
EP3704113B1 (en) | 2017-11-01 | 2023-10-11 | Bristol-Myers Squibb Company | Bridged bicyclic compounds as farnesoid x receptor modulators |
CN111511731B (zh) | 2017-11-01 | 2023-05-23 | 百时美施贵宝公司 | 作为法尼醇x受体调节剂的烯烃化合物 |
WO2019113236A1 (en) | 2017-12-06 | 2019-06-13 | Vivace Therapeutics, Inc. | Benzocarbonyl compounds |
CA3090130A1 (en) | 2018-02-02 | 2019-08-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
WO2019204505A2 (en) | 2018-04-18 | 2019-10-24 | Theras, Inc. | K-ras modulators with a vinyl sulfonamide moiety |
EP3802543A1 (en) | 2018-05-31 | 2021-04-14 | F. Hoffmann-La Roche AG | Therapeutic compounds |
JP2021535169A (ja) | 2018-09-03 | 2021-12-16 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Teadモジュレーターとして有用なカルボキサミドおよびスルホンアミド誘導体 |
WO2020073031A1 (en) | 2018-10-05 | 2020-04-09 | New York University | Fused bicyclic heterocycles as thereapeutic agents |
US20220402869A1 (en) | 2018-10-15 | 2022-12-22 | Dana-Farber Cancer Institute, Inc. | Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof |
EP3867242A1 (en) | 2018-10-15 | 2021-08-25 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
US20210403415A1 (en) | 2018-10-26 | 2021-12-30 | The Trustees Of Indiana University | Compounds and methods to attenuate tumor progression and metastasis |
EA202192019A1 (ru) | 2019-02-15 | 2021-11-02 | Новартис Аг | Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения |
KR20210143803A (ko) | 2019-03-15 | 2021-11-29 | 더 제너럴 하스피탈 코포레이션 | Tead 전사인자의 신규한 소분자 저해제 |
EP3947368A4 (en) | 2019-04-04 | 2023-01-04 | Dana-Farber Cancer Institute, Inc. | CDK2/5 DEGRADING AGENTS AND ASSOCIATED USES |
US20220227734A1 (en) | 2019-04-23 | 2022-07-21 | Dana-Farber Cancer Institute, Inc. | Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof |
JP2022534425A (ja) | 2019-05-31 | 2022-07-29 | イケナ オンコロジー, インコーポレイテッド | Tead阻害剤およびその使用 |
TW202108571A (zh) | 2019-05-31 | 2021-03-01 | 美商醫肯納腫瘤學公司 | Tead抑制劑及其用途 |
CA3155989A1 (en) | 2019-11-13 | 2021-05-20 | Jason Robert ZBIEG | Therapeutic compounds and methods of use |
IL293735A (en) | 2019-12-24 | 2022-08-01 | Dana Farber Cancer Inst Inc | Inhibitors of transcription factor enhanced transcription partner region and their uses |
CN115210227A (zh) | 2020-03-04 | 2022-10-18 | 基因泰克公司 | 作为tead抑制剂的异双功能分子 |
WO2021247634A1 (en) | 2020-06-03 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof |
WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
EP4255895A1 (en) | 2020-12-02 | 2023-10-11 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
KR20230149885A (ko) | 2021-01-25 | 2023-10-27 | 이케나 온콜로지, 인코포레이티드 | 폐암 치료에 사용하기 위한 3-(이미다졸-4-일)-4-(아미노)-벤젠설폰아마이드 tead 저해제와 egfr 저해제 및/또는 mek 저해제의 조합 |
-
2020
- 2020-05-29 TW TW109118208A patent/TW202108571A/zh unknown
- 2020-05-29 US US16/886,926 patent/US11274082B2/en active Active
- 2020-05-29 BR BR112021024108A patent/BR112021024108A2/pt unknown
- 2020-05-29 JP JP2021570918A patent/JP2022534426A/ja active Pending
- 2020-05-29 MX MX2021014443A patent/MX2021014443A/es unknown
- 2020-05-29 KR KR1020217043137A patent/KR20220030222A/ko unknown
- 2020-05-29 WO PCT/US2020/035098 patent/WO2020243415A2/en unknown
- 2020-05-29 AU AU2020282757A patent/AU2020282757A1/en active Pending
- 2020-05-29 SG SG11202113129UA patent/SG11202113129UA/en unknown
- 2020-05-29 CA CA3142351A patent/CA3142351A1/en active Pending
- 2020-05-29 EP EP20746750.7A patent/EP3976194A2/en active Pending
- 2020-05-29 CN CN202080050337.7A patent/CN114466839A/zh active Pending
-
2021
- 2021-11-25 IL IL288384A patent/IL288384A/en unknown
- 2021-11-26 CO CONC2021/0016015A patent/CO2021016015A2/es unknown
- 2021-11-30 CL CL2021003190A patent/CL2021003190A1/es unknown
-
2022
- 2022-01-03 US US17/646,787 patent/US11760728B2/en active Active
-
2023
- 2023-06-16 US US18/336,562 patent/US20240083854A1/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11827634B2 (en) | 2019-05-31 | 2023-11-28 | Janssen Pharmaceutica Nv | Small molecule inhibitors of NF-kB inducing kinase |
Also Published As
Publication number | Publication date |
---|---|
SG11202113129UA (en) | 2021-12-30 |
EP3976194A2 (en) | 2022-04-06 |
JP2022534426A (ja) | 2022-07-29 |
US20240083854A1 (en) | 2024-03-14 |
US20200407327A1 (en) | 2020-12-31 |
KR20220030222A (ko) | 2022-03-10 |
CN114466839A (zh) | 2022-05-10 |
CO2021016015A2 (es) | 2022-04-08 |
AU2020282757A1 (en) | 2021-12-23 |
CA3142351A1 (en) | 2020-12-03 |
IL288384A (en) | 2022-01-01 |
WO2020243415A2 (en) | 2020-12-03 |
BR112021024108A2 (pt) | 2022-03-22 |
US20220251048A1 (en) | 2022-08-11 |
WO2020243415A3 (en) | 2021-01-07 |
US11760728B2 (en) | 2023-09-19 |
US11274082B2 (en) | 2022-03-15 |
TW202108571A (zh) | 2021-03-01 |
MX2021014443A (es) | 2022-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021003191A1 (es) | Inhibidores de tead y usos de los mismos | |
CL2021003190A1 (es) | Inhibidores de tead y usos de los mismos | |
CO2021007068A2 (es) | Degradadores de irak y usos de los mismos | |
CO2022002759A2 (es) | Antagonistas de hpk1 y sus usos | |
CO2022008406A2 (es) | Degradadores de irak y usos de los mismos | |
CL2019003627A1 (es) | Anticuerpos anti-pd-1 y sus usos. (solicitud divisional 201900628) | |
CO2021013339A2 (es) | Degradadores de stat y usos de los mismos | |
CO2018000631A2 (es) | Compuestos bicíclicos como inhibidores de atx | |
CO2018000668A2 (es) | Nuevos compuestos bicíclicos como inhibidores duales de atx/ca | |
CL2018001360A1 (es) | Inhibidores triazol de acc y usos de los mismos | |
CO2017011151A2 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
CO2019009373A2 (es) | Compuestos heterocíclicos útiles como inhibidores duales de atx/ca. | |
CO2022001453A2 (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 | |
CO2020015747A2 (es) | Analogos de rapamicina y usos de los mismos | |
DOP2015000219A (es) | Compuestos de heteroarilo y sus usos | |
CL2017000576A1 (es) | Inhibidores de mk2 y sus usos | |
CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
CO2017011152A2 (es) | Nuevos compuestos bicíclicos como inhibidores duales de atx / ca. | |
CL2022002402A1 (es) | Inhibidores del eif4e y sus usos | |
CO2023008362A2 (es) | Degradadores de irak y sus usos | |
ECSP11011344A (es) | Nuevos anticuerpos anti-?5?1 y sus usos | |
CO2023014770A2 (es) | Degradadores de cdk2 y sus usos | |
ECSP21068097A (es) | Anticuerpos claudina 6 y usos de los mismos | |
CO2023006818A2 (es) | Degradadores de irak y sus usos | |
BR112021011124A2 (pt) | Anelossomos e métodos de uso |